Cargando…
Formate Might Be a Novel Potential Serum Metabolic Biomarker for Type 2 Diabetic Peripheral Neuropathy
BACKGROUND: As one of the most frequent complications of type 2 diabetes mellitus (T2DM), diabetic peripheral neuropathy (DPN) shows a profound impact on 50% of patients with symptoms of neuropathic pain, numbness and other paresthesia. No valid serum biomarkers for the prediction of DPN have been i...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10576463/ https://www.ncbi.nlm.nih.gov/pubmed/37842336 http://dx.doi.org/10.2147/DMSO.S428933 |
_version_ | 1785121127296663552 |
---|---|
author | Xu, Weisheng Xue, Wangsheng Zhou, Zeyu Wang, Jiying Qi, Hui Sun, Shiyu Jin, Tong Yao, Ping Zhao, Jian-Yuan Lin, Fuqing |
author_facet | Xu, Weisheng Xue, Wangsheng Zhou, Zeyu Wang, Jiying Qi, Hui Sun, Shiyu Jin, Tong Yao, Ping Zhao, Jian-Yuan Lin, Fuqing |
author_sort | Xu, Weisheng |
collection | PubMed |
description | BACKGROUND: As one of the most frequent complications of type 2 diabetes mellitus (T2DM), diabetic peripheral neuropathy (DPN) shows a profound impact on 50% of patients with symptoms of neuropathic pain, numbness and other paresthesia. No valid serum biomarkers for the prediction of DPN have been identified in the clinic so far. This study is to investigate the potential serum biomarkers for DPN firstly based on (1)H-Nuclear Magnetic Resonance ((1)H-NMR)-based metabolomics technique. METHODS: Thirty-six patients enrolled in this study were divided into two groups: 18 T2DM patients without DPN (T2DM group) and 18 T2DM patients with DPN (DPN group). Serum metabolites were measured via (1)H-NMR spectroscopy. Bioinformatic approaches including principal component analysis (PCA), orthogonal partial least squares-discriminant analysis (OPLS-DA), independent sample t-test, Fisher’s test, Pearson and Spearman correlation analysis, Stepwise multiple linear regression analysis and receiver operating characteristic (ROC) curve analysis were used to identify the potential altered serum biomarkers. RESULTS: A total of 20 metabolites were obtained and further analyzed. Formate was identified as the only potential biomarker that decreased in the DPN group with statistical significance after multiple comparisons (p<0.05). Formate also displayed a negative relationship with some elevated clinical markers in DPN. ROC curve analysis showed a good discriminative ability for formate in DPN with an area under the curve (AUC) value of 0.981. CONCLUSION: Formate could be considered a potential serum metabolic biomarker for DPN. The reduced level of formate in DPN may be associated with mitochondrial dysfunction and gut microbiota alteration. Monitoring the level of serum formate would be an important strategy for the early diagnosis of DPN and a supplement of formate may be a promising treatment for DPN in the future. |
format | Online Article Text |
id | pubmed-10576463 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-105764632023-10-15 Formate Might Be a Novel Potential Serum Metabolic Biomarker for Type 2 Diabetic Peripheral Neuropathy Xu, Weisheng Xue, Wangsheng Zhou, Zeyu Wang, Jiying Qi, Hui Sun, Shiyu Jin, Tong Yao, Ping Zhao, Jian-Yuan Lin, Fuqing Diabetes Metab Syndr Obes Original Research BACKGROUND: As one of the most frequent complications of type 2 diabetes mellitus (T2DM), diabetic peripheral neuropathy (DPN) shows a profound impact on 50% of patients with symptoms of neuropathic pain, numbness and other paresthesia. No valid serum biomarkers for the prediction of DPN have been identified in the clinic so far. This study is to investigate the potential serum biomarkers for DPN firstly based on (1)H-Nuclear Magnetic Resonance ((1)H-NMR)-based metabolomics technique. METHODS: Thirty-six patients enrolled in this study were divided into two groups: 18 T2DM patients without DPN (T2DM group) and 18 T2DM patients with DPN (DPN group). Serum metabolites were measured via (1)H-NMR spectroscopy. Bioinformatic approaches including principal component analysis (PCA), orthogonal partial least squares-discriminant analysis (OPLS-DA), independent sample t-test, Fisher’s test, Pearson and Spearman correlation analysis, Stepwise multiple linear regression analysis and receiver operating characteristic (ROC) curve analysis were used to identify the potential altered serum biomarkers. RESULTS: A total of 20 metabolites were obtained and further analyzed. Formate was identified as the only potential biomarker that decreased in the DPN group with statistical significance after multiple comparisons (p<0.05). Formate also displayed a negative relationship with some elevated clinical markers in DPN. ROC curve analysis showed a good discriminative ability for formate in DPN with an area under the curve (AUC) value of 0.981. CONCLUSION: Formate could be considered a potential serum metabolic biomarker for DPN. The reduced level of formate in DPN may be associated with mitochondrial dysfunction and gut microbiota alteration. Monitoring the level of serum formate would be an important strategy for the early diagnosis of DPN and a supplement of formate may be a promising treatment for DPN in the future. Dove 2023-10-10 /pmc/articles/PMC10576463/ /pubmed/37842336 http://dx.doi.org/10.2147/DMSO.S428933 Text en © 2023 Xu et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Xu, Weisheng Xue, Wangsheng Zhou, Zeyu Wang, Jiying Qi, Hui Sun, Shiyu Jin, Tong Yao, Ping Zhao, Jian-Yuan Lin, Fuqing Formate Might Be a Novel Potential Serum Metabolic Biomarker for Type 2 Diabetic Peripheral Neuropathy |
title | Formate Might Be a Novel Potential Serum Metabolic Biomarker for Type 2 Diabetic Peripheral Neuropathy |
title_full | Formate Might Be a Novel Potential Serum Metabolic Biomarker for Type 2 Diabetic Peripheral Neuropathy |
title_fullStr | Formate Might Be a Novel Potential Serum Metabolic Biomarker for Type 2 Diabetic Peripheral Neuropathy |
title_full_unstemmed | Formate Might Be a Novel Potential Serum Metabolic Biomarker for Type 2 Diabetic Peripheral Neuropathy |
title_short | Formate Might Be a Novel Potential Serum Metabolic Biomarker for Type 2 Diabetic Peripheral Neuropathy |
title_sort | formate might be a novel potential serum metabolic biomarker for type 2 diabetic peripheral neuropathy |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10576463/ https://www.ncbi.nlm.nih.gov/pubmed/37842336 http://dx.doi.org/10.2147/DMSO.S428933 |
work_keys_str_mv | AT xuweisheng formatemightbeanovelpotentialserummetabolicbiomarkerfortype2diabeticperipheralneuropathy AT xuewangsheng formatemightbeanovelpotentialserummetabolicbiomarkerfortype2diabeticperipheralneuropathy AT zhouzeyu formatemightbeanovelpotentialserummetabolicbiomarkerfortype2diabeticperipheralneuropathy AT wangjiying formatemightbeanovelpotentialserummetabolicbiomarkerfortype2diabeticperipheralneuropathy AT qihui formatemightbeanovelpotentialserummetabolicbiomarkerfortype2diabeticperipheralneuropathy AT sunshiyu formatemightbeanovelpotentialserummetabolicbiomarkerfortype2diabeticperipheralneuropathy AT jintong formatemightbeanovelpotentialserummetabolicbiomarkerfortype2diabeticperipheralneuropathy AT yaoping formatemightbeanovelpotentialserummetabolicbiomarkerfortype2diabeticperipheralneuropathy AT zhaojianyuan formatemightbeanovelpotentialserummetabolicbiomarkerfortype2diabeticperipheralneuropathy AT linfuqing formatemightbeanovelpotentialserummetabolicbiomarkerfortype2diabeticperipheralneuropathy |